Cargando…

Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China

CONTEXT: In 2020, the terminology of metabolic dysfunction–associated fatty liver disease (MAFLD) was proposed to replace nonalcoholic fatty liver disease (NAFLD). OBJECTIVES: This work aimed to investigate the prevalence and incidence of MAFLD and evaluate its effects on incident extrahepatic disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Yebei, Chen, Hongli, Liu, Yuexing, Hou, Xuhong, Wei, Li, Bao, Yuqian, Yang, Chunguang, Zong, Geng, Wu, Jiarui, Jia, Weiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684479/ https://www.ncbi.nlm.nih.gov/pubmed/34508601 http://dx.doi.org/10.1210/clinem/dgab641

Ejemplares similares

Osteocalcin and Risks of Incident Diabetes and Diabetic Kidney Disease: A 4.6-Year Prospective Cohort Study
por: Ye, Xiaoqi, et al.
Publicado: (2022)

MAFLD and NAFLD in the prediction of incident chronic kidney disease
por: Kwon, So Yoon, et al.
Publicado: (2023)

Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022)

MAFLD: a multisystem disease
por: Pipitone, Rosaria Maria, et al.
Publicado: (2023)

MAFLD and Celiac Disease in Children
por: Scapaticci, Serena, et al.
Publicado: (2023)

FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China
por: Liu, Dan, et al.
Publicado: (2021)

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2021)

The Significance of Screening for Microvascular Diseases in Chinese Community-Based Subjects with Various Metabolic Abnormalities
por: Pang, Can, et al.
Publicado: (2014)

Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
por: Drożdż, Karolina, et al.
Publicado: (2021)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
por: Boccatonda, Andrea, et al.
Publicado: (2023)

Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
por: Cao, Weijie, et al.
Publicado: (2021)

Serum Glycated Albumin Levels Are Affected by Alcohol in Men of the Jinuo Ethnic Group in China
por: Zhu, Chaoyu, et al.
Publicado: (2021)

MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
por: Huang, Jiaofeng, et al.
Publicado: (2021)

New-Onset Acute Kidney Disease Post COVID-19 Vaccination
por: Li, Yebei, et al.
Publicado: (2022)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
por: Yang, Chenyu, et al.
Publicado: (2022)

Role of Insulin Resistance in MAFLD
por: Sakurai, Yoshitaka, et al.
Publicado: (2021)

The Gut Microbiome and Ferroptosis in MAFLD
por: Ji, Jie, et al.
Publicado: (2023)

NAFLD/MAFLD: New Evidence
por: Mantovani, Alessandro, et al.
Publicado: (2023)

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
por: Kawaguchi, Takumi, et al.
Publicado: (2022)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease
por: Musio, Alessandra, et al.
Publicado: (2023)

The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease
por: Kulkarni, Anand V., et al.
Publicado: (2023)

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
por: Guo, Qin, et al.
Publicado: (2023)

Gender differences in the ideal cutoffs of visceral fat area for predicting MAFLD in China
por: Yu, Pingping, et al.
Publicado: (2022)

MAFLD and CKD: An Updated Narrative Review
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022)

MAFLD: How is it different from NAFLD?
por: Gofton, Cameron, et al.
Publicado: (2023)

Comparison of MAFLD and NAFLD Characteristics in Children
por: Xing, Yunfei, et al.
Publicado: (2023)

Screening for MAFLD: who, when and how?
por: Pal, Shreya C., et al.
Publicado: (2023)

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020)

The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases
por: Tsutsumi, Tsubasa, et al.
Publicado: (2023)

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
por: Griffett, Kristine, et al.
Publicado: (2023)

Ten-year changes in the prevalence of overweight, obesity and central obesity among the Chinese adults in urban Shanghai, 1998–2007 — comparison of two cross-sectional surveys
por: Hou, Xuhong, et al.
Publicado: (2013)

Serum electrolyte levels in relation to macrovascular complications in Chinese patients with diabetes mellitus
por: Wang, Shenqi, et al.
Publicado: (2013)

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
por: Kaya, Eda, et al.
Publicado: (2022)

A greater ratio of thigh subcutaneous fat to abdominal fat is associated with protection against non-alcoholic fatty liver disease
por: Liang, Yebei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uvmkasfee0ofh1hqh9q9sl10uv